TPCW
WST icon

TD Private Client Wealth’s West Pharmaceutical WST Stock Holding History

TD Private Client Wealth’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$955K Sell
2,661
-49
-2% -$15K 0.02% 374
2026
Q1 		$679K Sell
2,710
-972
-26% -$242K 0.01% 429
2025
Q4 		$1.01M Sell
3,682
-633
-15% -$173K 0.02% 361
2025
Q3 		$1.13M Sell
4,315
-783
-15% -$190K 0.03% 336
2025
Q2 		$1.12M Sell
5,098
-92
-2% -$19.7K 0.03% 335
2025
Q1 		$1.16M Buy
5,190
+648
+14% +$179K 0.03% 316
2024
Q4 		$1.49M Buy
4,542
+305
+7% +$96K 0.04% 281
2024
Q3 		$1.27M Sell
4,237
-137
-3% -$42K 0.04% 329
2024
Q2 		$1.44M Buy
4,374
+790
+22% +$279K 0.05% 295
2024
Q1 		$1.42M Sell
3,584
-64
-2% -$23.7K 0.05% 297
2023
Q4 		$1.28M Sell
3,648
-40
-1% -$14.2K 0.05% 300
2023
Q3 		$1.38M Sell
3,688
-202
-5% -$78.1K 0.06% 269
2023
Q2 		$1.49M Sell
3,890
-235
-6% -$84K 0.06% 269
2023
Q1 		$1.43M Sell
4,125
-46
-1% -$13.4K 0.06% 272
2022
Q4 		$982K Buy
4,171
+118
+3% +$28K 0.05% 326
2022
Q3 		$997K Sell
4,053
-120
-3% -$36.6K 0.05% 311
2022
Q2 		$1.26M Sell
4,173
-643
-13% -$209K 0.06% 283
2022
Q1 		$1.98M Sell
4,816
-328
-6% -$128K 0.08% 238
2021
Q4 		$2.41M Buy
5,144
+295
+6% +$127K 0.1% 206
2021
Q3 		$2.06M Sell
4,849
-575
-11% -$242K 0.09% 228
2021
Q2 		$1.95M Sell
5,424
-385
-7% -$127K 0.08% 241
2021
Q1 		$1.64M Buy
5,809
+484
+9% +$139K 0.08% 259
2020
Q4 		$1.51M Buy
5,325
+280
+6% +$78.6K 0.08% 255
2020
Q3 		$1.39M Buy
5,045
+604
+14% +$160K 0.08% 247
2020
Q2 		$1.01M Buy
4,441
+1,465
+49% +$288K 0.06% 279
2020
Q1 		$453K Buy
2,976
+202
+7% +$31.1K 0.03% 333
2019
Q4 		$417K Buy
+2,774
New +$404K 0.03% 373

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

TD Private Client Wealth's WST Position: Q2 2026 in Review

TD Private Client Wealth reduced its West Pharmaceutical (WST) stake by 1.8% in Q2 2026, selling an estimated $15K and leaving 2,661 shares worth $955K. The position accounts for 0.02% of the portfolio, ranked #374.

TD Private Client Wealth first reported a position in WST in Q4 2019 and has held it in 27 quarters since. The position peaked at $2.41M in Q4 2021. 831 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • TD Private Client Wealth held 2,661 shares of West Pharmaceutical worth $955K as of Q2 2026.
  • TD Private Client Wealth sold 49 West Pharmaceutical shares in Q2 2026, an estimated $15K.
  • West Pharmaceutical made up 0.02% of TD Private Client Wealth's portfolio in Q2 2026, its #374 holding.
  • TD Private Client Wealth first reported a position in West Pharmaceutical in Q4 2019 and has held it in 27 quarters since.
  • TD Private Client Wealth's West Pharmaceutical position peaked at $2.41M in Q4 2021.
  • 831 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.